Onkološki inštitut Ljubljana (OILJ)
  • Abemaciclib for the treatment of HR+HER2− metastatic breast cancer [Elektronski vir] : an institutional experience
    Matos, Erika ...
    Abemaciclib in combination with endocrine therapy is a standard first- or laterline of treatment for HR+/HER2− metastatic breast cancer (MBC). Real-world studies provide valuable addition to pivotal ... trials by including a heterogeneous patient population, particularly subgroups that are often underrepresented (e.g., elderly patients). This study retrospectively collected data on the efficacy and safety of abemaciclib in a real-world patient population. The safety and efficacy of the treatment were consistent with the pivotal studies, including in elderly patients. Comparable survival outcomes were observed between the first two lines of treatment. Additionally, metastatic disease survival was greatly prolonged, exceeding 5 years compared to historical data. The study provides further reassurance that dose reductions do not affect survival. The safety profile of abemaciclib was consistent with previous findings, and no new adverse events (AEs) were identified. Although abemaciclib was well tolerated in elderly patients, the careful monitoring and management of AEs is still warranted.
    Vir: Cancers [Elektronski vir]. - ISSN 2072-6694 (Vol. 16, no. 10, 2024, str. 1824-1-1824-10)
    Vrsta gradiva - e-članek ; neleposlovje za odrasle
    Leto - 2024
    Jezik - angleški
    COBISS.SI-ID - 195245315

    Povezava(-e):

    https://www.mdpi.com/2072-6694/16/10/1828
    DOI

Vnos na polico